HIV primary drug resistance and associated HIV risk factors among HIV positive blood donors in Brazil from 2007 to 2017.

Autor: Moreira CHV; Instituto de Infectologia 'Emílio Ribas', São Paulo, Brazil.; Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina (FMUSP) da Universidade de São Paulo, São Paulo, Brazil., Salomon T; Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina (FMUSP) da Universidade de São Paulo, São Paulo, Brazil., Alencar CS; Laboratório de Medicina Laboratorial LIM 03- HCFMUSP, São Paulo, Brazil., Gonçalez TT; Vitalant Research Institute, San Francisco, California, USA., Sabino EC; Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina (FMUSP) da Universidade de São Paulo, São Paulo, Brazil., Preiss L; RTI - Research Triangle Institute, Durham, North Carolina, USA., Loureiro P; Fundação HEMOPE, Recife, Brazil., Lopes ME; Fundação HEMORIO, Rio de Janeiro, Brazil., Teixeira CM; Fundação HEMOMINAS, Belo Horizonte, Brazil., Mundim M; Fundação HEMORIO, Rio de Janeiro, Brazil., Carneiro-Proietti AB; Fundação HEMOMINAS, Belo Horizonte, Brazil., de Almeida-Neto C; Departamento de Aféreses, Fundação Pró-Sangue, Hemocentro de São Paulo, Sao Paulo, Brazil.; Disciplina de Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Custer B; Vitalant Research Institute, San Francisco, California, USA.; Department of Laboratory Medicine, UCSF, San Francisco, California, USA.
Jazyk: angličtina
Zdroj: Transfusion medicine (Oxford, England) [Transfus Med] 2021 Apr; Vol. 31 (2), pp. 104-112. Date of Electronic Publication: 2021 Mar 04.
DOI: 10.1111/tme.12766
Abstrakt: Background: Acquisition of HIV primary drug resistant (PDR) infection can lead to poor virologic and clinical outcomes in individuals and hampers public health efforts in epidemic control. Monitoring PDR in HIV-positive blood donors can be used to inform nationwide trends in the spread of drug-resistant HIV strains.
Methods: We conducted a cross-sectional study using genetic sequence analysis to assess HIV pol sequences, PDR, and risk factors for infection using audio computer-assisted structured interviews in four large blood centers in Brazil from 2007 to 2017.
Results: Of 716 HIV-positive blood donors, 504 (70.4%) were successfully sequenced. HIV clade B (73.2%) was the most prevalent subtype, followed by a mix of non-B (21.2%) sub-types. A twofold increase (from 4% to 8%) in recombinants prevalence was observed during the study period. Sixty-four (12.7%) presented PDR. Overall, HIV PDR prevalence remained stable during the study period. Drug resistance mutations for non-nucleoside reverse transcriptase inhibitors were found in 39 (7.7%) donors, while for nucleoside reverse transcriptase inhibitors were found in 26 (5.1%), and for protease inhibitors in 24 (4.8%) of HIV-infected donors. We did not find statistically significant differences in demographics, behavioural risk factors, or HIV genotypes when comparing volunteers with and without PDR.
Conclusion: The HIV PDR rate among donors remained stable during the study period. HIV-positive blood donors can be an informative population to monitor primary HIV resistance and ultimately may help to increase the knowledge and awareness of HIV risk factors and PDR.
(© 2021 British Blood Transfusion Society.)
Databáze: MEDLINE
Externí odkaz: